Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Common Equity: 2016-2025

Historic Common Equity for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to -$115.4 million.

  • UroGen Pharma's Common Equity fell 552.31% to -$115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$115.4 million, marking a year-over-year decrease of 552.31%. This contributed to the annual value of -$8.8 million for FY2024, which is 86.50% up from last year.
  • As of Q3 2025, UroGen Pharma's Common Equity stood at -$115.4 million, which was down 23.59% from -$93.4 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Common Equity high stood at $76.5 million for Q1 2021, and its period low was -$138.4 million during Q2 2023.
  • Over the past 3 years, UroGen Pharma's median Common Equity value was -$46.5 million (recorded in 2025), while the average stood at -$55.5 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 1,162.18% in 2022, then surged by 160.76% in 2024.
  • Over the past 5 years, UroGen Pharma's Common Equity (Quarterly) stood at $8.4 million in 2021, then slumped by 1,162.18% to -$89.4 million in 2022, then rose by 27.02% to -$65.2 million in 2023, then surged by 86.50% to -$8.8 million in 2024, then slumped by 552.31% to -$115.4 million in 2025.
  • Its Common Equity stands at -$115.4 million for Q3 2025, versus -$93.4 million for Q2 2025 and -$46.5 million for Q1 2025.